Purpose: The three positron emission tomography (PET) imaging compounds: (2,4)-4-[F]Fluoroglutamine ([F]FGln), -[methyl-C]Methionine ([C]Met), and 2-deoxy-2-[F]fluoro--glucose ([F]FDG) were investigated to contrast their ability to image orthotopic BT4C gliomas in BDIX rats. Two separate small animal imaging systems were compared for their tumor detection potential. Dynamic acquisition of [F]FGln was evaluated with multiple pharmacokinetic models for future quantitative comparison.
Procedures: Up to four imaging studies were performed on each orthotopically grafted BT4C glioma-bearing BDIX rat subject (n = 16) on four consecutive days. First, a DOTAREM contrast enhanced MRI followed by attenuation correction CT and dynamic PET imaging with each radiopharmaceutical (20 min [C]Met, 60 min [F]FDG, and 60 min [F]FGln with either the Molecubes PET/CT (n = 5) or Inveon PET/CT cameras (n = 11). brain autoradiography was completed for each radiopharmaceutical and [F]FGln pharmacokinetics were studied by injecting 40 MBq into healthy BDIX rats (n = 10) and collecting blood samples between 5 and 60 min. Erythrocyte uptake, plasma protein binding and plasma parent-fraction were combined to estimate the total blood bioavailability of [F]FGln over time. The corrected PET-image blood data was then applied to multiple pharmacokinetic models.
Results: Average BT4C tumor-to-healthy brain tissue uptake ratios (TBR) for PET images reached maxima of: [F]FGln TBR: 1.99 ± 0.19 (n = 13), [F]FDG TBR: 1.41 ± 0.11 (n = 6), and [C]Met TBR: 1.08 ± 0.08, (n = 12) for the dynamic PET images. Pharmacokinetic modeling in dynamic [F]FGln studies suggested both reversible and irreversible uptake play a similar role. Imaging with Inveon and Molecubes yielded similar end-result ratios with insignificant differences (p > 0.25).
Conclusions: In orthotopic BT4C gliomas, [F]FGln may offer improved imaging [C]Met and [F]FDG. No significant difference in normalized end-result data was found between the Inveon and Molecubes camera systems. Kinetic modelling of [F]FGln uptake suggests that both reversible and irreversible uptake play an important role in BDIX rat pharmacokinetics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530378 | PMC |
| http://dx.doi.org/10.3389/fonc.2021.730358 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Value of 18 F-(2S,4R)-4-Fluoroglutamine PET/CT in Glioma.
Clin Nucl Med
December 2024
From the State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, China.
Propose: The aim of this study was to evaluate the clinical application value of 18 F-FGln PET/CT in glioma.
Patients And Methods: Patients with suspected gliomas by MRI were included in this study. Static and/or dynamic brain 18 F-FGln PET/CT was performed.
The Potential Utility of (2S,4R)-4-[F]fluoroglutamine as a Novel Metabolic Imaging Marker for Inflammation Explored by Rat Models of Arthritis and Paw Edema.
Mol Imaging Biol
November 2024
Department of Psychiatry and Behavioral Health, Stony Brook University School of Medicine, 101 Nicolls Rd, HSC T10-041L, Stony Brook, NY, 11794, USA.
Purpose: (2S,4R)-4-[F]fluoroglutamine ([F]FGln) is a promising metabolic imaging marker in cancer. Based on the fact that major inflammatory cells are heavily dependent on glutamine metabolism like cancer cells, we explored the potential utility of [F]FGln as a metabolic imaging marker for inflammation in two rat models: carrageenan-induced paw edema (CIPE) and collagen-induced arthritis (CIA).
Procedures: The CIPE model (n = 4) was generated by injecting 200 µL of 3% carrageenan solution into the left hind paw three hours before the PET.
Purpose: ()-4-[F]fluoroglutamine ([F]FGln) is a promising metabolic imaging marker in cancer. Based on the fact that major inflammatory cells are heavily dependent on glutamine metabolism like cancer cells, we explored the potential utility of [F]FGln as a metabolic imaging marker for inflammation in two rat models: carrageenan-induced paw edema (CIPE) and collagen-induced arthritis (CIA).
Procedures: The CIPE model (n = 4) was generated by injecting 200 μL of 3% carrageenan solution into the left hind paw three hours before the PET.
KRAS Mutation Detection with (2,4)-4-[F]FGln for Noninvasive PDAC Diagnosis.
Mol Pharm
April 2024
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis and nonspecific symptoms and progresses rapidly, is the most common pancreatic cancer type. Inhibitors targeting KRAS G12D and G12C mutations have been pivotal in PDAC treatment. Cancer cells with different KRAS mutations exhibit various degrees of glutamine dependency; in particular, cells with KRAS G12D mutations exhibit increased glutamine uptake.
View Article and Find Full Text PDFEvaluation of (2S,4S)-4-[F]FEBGln as a Positron Emission Tomography Tracer for Tumor Imaging.
Mol Pharm
October 2023
Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing 100069, China.
Glutamine metabolism-related tracers have the potential to visualize numerous tumors because glutamine is the second largest source of energy for tumors. (2S,4S)-4-[F]FEBGln was designed by introducing [F]fluoroethoxy benzyl on carbon-4 of glutamine. The aim of this study was to investigate the pharmacokinetic properties and tumor positron emission tomography (PET) imaging characteristics of (2S,4S)-4-[F]FEBGln in detail.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!